Menopause Practitioner Perspective on the American Society of Bone and Mineral Research Task Force Report on Atypical Femoral Fracture.
Document Type
Article
Publication Date
10-1-2013
Abstract
CLINICAL SCENARIO: One of your patients, a 59-year-old postmenopausal Asian woman (menopause, age 52), took hormone therapy for about one year for her menopause symptoms. When she was 54, her mother (age 80) suffered a hip fracture, and she requested a bone density test at her next gynecology visit. The t-score results were spine, -1.1; total hip, -1.8; and femoral neck, -2.1, all in the osteopenic range. After some discussion, she was started on alendronate 70 mg once a week, together with calcium and vitamin D. Follow-up dual-energy x-ray absorptiometry testing after 2 and 5 years of therapy showed increases in bone mineral density, resulting in t-score improvements of about 0.3 to 0.5 units (spine was now normal; femoral neck was -1.8). The Fracture Risk Assessment Tool estimated her 10-year risk of hip fracture to be 0.4% and her 10-year risk of any of 4 major osteoporotic fractures to be 7.5%. During her most recent gynecology visit, she expressed concern about unusual femoral fractures being linked to long-term use of alendronate. She asks if there is reason for her to stop using this drug.
Publication Title
Menopause (New York, N.Y.)
Volume
20
Issue
10
First Page
1092
Last Page
1097
Recommended Citation
Ettinger, B., Stuenkel, C., & Schnatz, P. (2013). Menopause Practitioner Perspective on the American Society of Bone and Mineral Research Task Force Report on Atypical Femoral Fracture.. Menopause (New York, N.Y.), 20 (10), 1092-1097. https://doi.org/https://doi.org/10.1097/GME.0b013e3182a7c57b